Demand for Minimally Invasive Procedures Boosts Sale of Cardiac Implants

The implantable cardiac devices market has demonstrated robust growth in recent years and is poised for continued expansion. The market size increased from $11.36 billion in 2023 to an estimated $12.34 billion in 2024, reflecting a compound annual growth rate (CAGR) of 8.7%. This growth in the historic period is primarily driven by advances in medical technology, a rising prevalence of cardiovascular diseases, an aging population, and improvements in device reliability and longevity. Increased awareness and early diagnosis of heart conditions have further supported market growth.

Looking ahead, the market is projected to grow to $17.31 billion by 2028, at a slightly higher CAGR of 8.8%. Key drivers during this forecast period include technological advancements in device functionality, the rising demand for minimally invasive procedures, and increased healthcare spending, especially in emerging markets. The expansion of healthcare infrastructure and an aging global population also contribute to this positive outlook.

Emerging Trends

The forecast period highlights several trends shaping the market: 

- Integration of digital health and remote monitoring for better patient management. 

- Development of next-generation implantable devices with enhanced features. 

- Growth in personalized and patient-specific cardiac solutions. 

- Focus on cost-effectiveness and value-based healthcare. 

- Increasing emphasis on preventive cardiology and early intervention.

Impact of Rising Cardiovascular Diseases 

The increasing prevalence of cardiovascular diseases is a major factor propelling market growth. Contributing factors include: 

- Poor diets and sedentary lifestyles. 

- Obesity, diabetes, and hypertension. 

- Aging populations and rising stress levels. 

Implantable cardiac devices, such as those for managing heart failure, arrhythmias, and coronary artery disease, address these rising challenges. For example, the Singapore Heart Foundation (SHF) reported that ischemic heart disease caused 5,302 deaths in 2024, up slightly from 5,290 in 2022. Such statistics highlight the growing need for innovative solutions and investments in cardiac device development to enhance treatment outcomes for the expanding patient population.